Skip to content
2000
Volume 14, Issue 10
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Breast cancer (BC) is the leading cause of death among women all over the world. Estrogen receptor (ER) based therapy is one of the major approaches to target BC and is associated with various problems such as primary as well as secondary resistance. ER signaling is a complex pathway as many factors are involved; including several types of ERs and their associated co-regulators. Increasing understanding of ER signals results in new approaches targeting towards BCs. In this context, ER co-regulators have been explored and many modulators of ER co-regulators have been found out. EGFR and mTOR pathways also have significant impact on BC endocrine therapy because of the complex crosstalk mechanism which is responsible for primary and secondary resistance. Triple negative breast cancer (TNBC) is majorly associated with BRCA mutations. Currently there is no approved targeted therapy available in such form of cancer. Although PARP inhibitors seem to be suitable candidates for it. The present review is focused on the current scenario of ER, EGFR, as well as mTOR signaling target therapy. We have also discussed the current status of PARP inhibitors in BC chemotherapy.

Loading

Article metrics loading...

/content/journals/acamc/10.2174/1871520614666140407114853
2014-12-01
2025-06-24
Loading full text...

Full text loading...

/content/journals/acamc/10.2174/1871520614666140407114853
Loading

  • Article Type:
    Research Article
Keyword(s): Breast cancer; chemotherapy; crosstalk; resistance; targeting
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test